This study aimed to identify the role of mouse fibroblast-mediated c-Jun and IGF-1 signaling in the therapeutic effect of finasteride on benign prostatic epithelial cells. BPH-1 cells, alone or with fibroblasts (c-Jun+/+ or c-Jun-/-), were implanted subcutaneously in male nude mice who were then treated with finasteride. The degrees of cell proliferation, apoptosis, and sizes of the xenografts ...

A number of naturally-occurring or synthetic chemicals have been reported to exhibit prostate chemopreventive effects. Synthetic 5α-reductase (5-AR) inhibitors, e.g. finasteride and durasteride, gained special interests as possible prostate chemopreventive agents. Indeed, two large-scale epidemiological studies have demonstrated that finasteride or durasteride significantly reduced the incidenc...

Finasteride is the 5alpha-reductase inhibitor that received clinical approval for the treatment of human benign prostate hyperplasia and androgenetic alopecia. The 5alpha-reductase is enzyme responsible for the reduction of testosterone to dihydrostestosterone, progesterone to dihydroprogesterone and deoxycorticosterone to dihydrodeoxycorticosterone, steroids modulating the action of gamma-amin...

background: the secretion of thyroxin (t4) as the main hormone of thyroid gland is regulated by androgens. the present study aimed to evaluate the effect of testosterone and finasteride administration and castration on serum levels of t4 and to show the effect of this regulation on total body weight, weight of testis, and the weight of prostate. methods: male adult rats (n = 32) were divided in...

BACKGROUND Finasteride, a specific inhibitor of type II 5alpha-reductase, decreases serum and scalp dihydrotestosterone and has been shown to be effective in men with vertex male pattern hair loss. OBJECTIVE This study evaluated the efficacy of finasteride 1 mg/day in men with frontal (anterior/mid) scalp hair thinning. METHODS This was a 1-year, double-blind, placebo-controlled study follo...

We investigated the effects of finasteride, a 5alpha-reductase inhibitor, on cell death machinery through the induction of apoptosis in an in vitro model for prostate cancer. Finasteride treatment of the LNCaP hormone-dependent human prostate cancer cell line caused the loss of cell viability and accelerated apoptosis in a concentration-dependent manner. The contents of immunoreactive procaspas...

Benign prostate hyperplasia and prostate cancer are major public health problems. We report herein that daily treatment of male rats with 50, 100 or 150 mg quercetin per kg body weight resulted in serum concentrations of quercetin equivalent to 25.3 microM, 43.3 microM and 54.3 microM respectively. Concomitantly, serum testosterone levels were increased by 1.79-, 1.83- and 3.48-fold, while seru...

Finasteride (a synthetic 5-alpha-reductase inhibitor) is used for the treatment of male pattern baldness and benign prostatic hyperplasia. There have been few reports on pregnancy outcomes after paternal exposure to finasteride either prior to or during pregnancy. Nineteen cases with documented paternal exposure to finasteride either prior to or during pregnancy were identified through the Kore...

Finasteride (a synthetic 5-alpha-reductase inhibitor) is used for the treatment of male pattern baldness and benign prostatic hyperplasia. There have been few reports on pregnancy outcomes after paternal exposure to finasteride either prior to or during pregnancy. Nineteen cases with documented paternal exposure to finasteride either prior to or during pregnancy were identified through the Kore...

INTRODUCTION The use of the 5-alpha reductase inhibitors (5-ARIs) finasteride and dutasteride for prostate cancer prevention is still under debate. The FDA recently concluded that the increased prevalence of high-grade tumors among 5-ARI-treated patients must not be neglected, and they decided to disallow the use of 5-ARIs for prostate cancer prevention. This study was conducted to verify the e...